How to titrate up safely on a GLP-1
Standard titration is one dose level every four weeks. The published schedule is a default, not a law. Here is what to do when the standard schedule does not fit your tolerance.
The standard semaglutide and tirzepatide titration schedule is published in every prescribing information sheet: increase one dose level every 4 weeks until you reach the maintenance dose. This is what your program will default to.
For about 60-70% of patients, the standard schedule works. For the rest, slowing down or holding a dose makes the difference between continuing treatment and quitting. This post explains when and how.
Standard semaglutide titration (Wegovy / compounded)
| Week | Dose | Note |
|---|---|---|
| 1-4 | 0.25mg / week | Starting dose. Side effects most pronounced. |
| 5-8 | 0.5mg / week | First escalation. Side effects often resurge briefly. |
| 9-12 | 1.0mg / week | Second escalation. |
| 13-16 | 1.7mg / week | Third escalation. Many patients see meaningful weight loss starting here. |
| 17+ | 2.4mg / week | Maintenance dose. |
Standard tirzepatide titration (Zepbound / compounded)
| Week | Dose | Note |
|---|---|---|
| 1-4 | 2.5mg / week | Starting dose. |
| 5-8 | 5mg / week | First escalation. |
| 9-12 | 7.5mg / week | Second escalation. |
| 13-16 | 10mg / week | Third escalation. Often the lowest effective maintenance dose. |
| 17+ | 12.5mg or 15mg / week | Maximum doses. Reserved for patients needing more weight loss. |
Signs the standard schedule is too aggressive
- Persistent nausea or vomiting more than 2 weeks after a dose increase
- Weight loss greater than 2.5lb (~1kg) per week — too fast, suggests body is in stress response
- Resting heart rate increase of more than 5-10 bpm
- Inability to eat enough to maintain protein intake (1g per kg)
- Persistent fatigue that doesn't resolve with adequate sleep
If any of these are present at your current dose, hold for an additional 2-4 weeks before escalating. There is no penalty for slow titration; your terminal weight loss outcome at 12 months is essentially the same whether you reached maintenance dose at week 16 or week 28.
Signs the standard schedule is too slow
- Minimal-to-no GI side effects after 4 weeks at current dose
- Weight loss less than 0.5lb (~0.2kg) per week at non-starting dose
- Subjective hunger has not changed
If all three are present, you may be a sub-responder at this dose. Faster titration is rarely the answer; switching from semaglutide to tirzepatide is usually more effective for non-responders. Talk to your prescriber.
When to dose-hold vs dose-down
Dose-hold: Stay at the current dose for an additional 2-4 weeks, then reattempt the next escalation. Use when side effects are tolerable but persistent. Most common adjustment.
Dose-down: Drop back one level to the previously tolerated dose. Use when a recent escalation produced severe side effects. Rare but appropriate for severe vomiting, dehydration, or persistent gastroparesis-like symptoms.
Stop entirely: Reserved for serious adverse events (pancreatitis, severe allergic reaction, persistent gastroparesis). Talk to your prescriber the same day.
Microdosing as a stop-gap
Some programs (notably Noom Med) offer microdose protocols starting at 0.1mg semaglutide instead of 0.25mg. There is no clinical trial evidence that microdosing produces better outcomes than standard titration in tolerant patients, but for patients who failed standard 0.25mg due to severe side effects, microdosing has anecdotal support as a way to extend tolerance.
Microdose is not a magic trick. The lower the starting dose, the longer titration takes, and weight loss correlates with dose reached. Use it as a tolerance bridge, not a permanent strategy.
The general rule
Slower titration costs almost nothing in terminal weight-loss outcomes. It costs a lot in side-effect-driven discontinuation. If you're not sure, hold a dose for an extra month. Your year-one weight loss number will be within 1-2 percentage points of the patient who pushed through the standard schedule.